Weight problems medication, to date solely obtainable by injection, could quickly be in tablet type : NPR

AYESHA RASCOE, HOST:

Medication like Wegovy and Ozempic have develop into more and more standard choices for thousands and thousands of people that need to attain a more healthy weight. However the medication, taken as weekly injections, aren’t for everyone or each pockets. That is why experimental capsules that might do the identical factor are drawing a lot consideration. A Wegovy-style tablet is predicted to win approval from the Meals and Drug Administration by the top of the yr. NPR prescribed drugs correspondent Sydney Lupkin is right here to speak with us about that risk. Good to have you ever right here, Sydney.

SYDNEY LUPKIN, BYLINE: Thanks for having me.

RASCOE: Why hasn’t there been a tablet model of those medication till now? I imply, it looks like one thing lots of people would need.

LUPKIN: Yeah. I imply, it is a good query. And there kind of is. It is referred to as Rybelsus, but it surely’s solely accredited for Sort 2 diabetes. It is made by Novo Nordisk, which is identical firm that makes Ozempic for Sort 2 diabetes and Wegovy for weight problems. But it surely’s a decrease dose of the lively ingredient these injectable medication share – semaglutide. The brand new tablet could be the next dose geared toward sufferers with weight problems, and research present its efficacy is fairly near Wegovy’s. Tracy Zvenyach is the director of coverage technique and alliances on the nonprofit Weight problems Motion Coalition. She says extra choices could be a giant deal.

TRACY ZVENYACH: The affected person neighborhood within the weight problems area has been residing with out – gone with out remedy for therefore lengthy. So new improvements, new remedies to deal with this continual illness – all are welcome. All are thrilling.

LUPKIN: She says a whole lot of sufferers are hopeful concerning the new capsules, significantly in the event that they’ve had a tough time accessing the injections for one purpose or one other.

RASCOE: OK. So how would this new tablet work? Is it the identical because the injectable variations?

LUPKIN: So semaglutide, that lively ingredient, will get damaged down fairly shortly within the abdomen – too shortly to really get absorbed and do its job. That is why it is largely been an injectable. So Novo Nordisk added one thing to it to repair that. It is a chemical with a protracted title, however the abbreviation is S-N-A-C – SNAC. Andrea Traina, one in every of Novo Nordisk’s weight problems administrators, defined the way it works.

ANDREA TRAINA: If you concentrate on dropping an Alka-Seltzer pill in a glass of water, that fast fizzy response that happens – that’s what occurs in your abdomen as quickly as this pill hits the bottom of your abdomen, hits that abdomen wall.

LUPKIN: It creates this fizzy atmosphere simply across the tablet, blocking the abdomen acids from breaking it down too shortly and giving it sufficient time to get absorbed into the bloodstream. It takes about half-hour. So the tablet must be taken on an empty abdomen, and you may’t eat or take different medicines till it is absorbed.

RASCOE: OK. It looks like which may flip no less than some folks off. What have you ever heard from sufferers?

LUPKIN: Yeah. Effectively, there are different standard medication that folks already take that should be taken the identical means, so it isn’t a deal breaker for everybody. However not everyone seems to be . If the injections are already working properly for them, this could be a day by day tablet. The injections are weekly. However the large hope from sufferers is that this tablet shall be cheaper and get higher insurance coverage protection than the injections. One individual informed me they only hope it is inexpensive than their mortgage.

Dr. Richard Siegel is an endocrinologist at Tufts Medical Heart.

RICHARD SIEGEL: However one of many large issues with the entire medicines on this enviornment has been the associated fee, and might we equitably get these medicines to the hundreds – you already know, thousands and thousands, actually – of people that would possibly profit from them?

LUPKIN: He says three-quarters of the messages he will get from sufferers are about these medication, and a whole lot of them are coping with renewals and insurance coverage corporations. His workplace is staffed to deal with that, however not each physician’s workplace is. When some folks lose insurance coverage protection, they will afford a number of hundred {dollars} a month to purchase immediately from the drug producers. However lots of people cannot, even with latest firm reductions that make it as little as $200 a month in some instances.

RASCOE: So do you assume the capsules really shall be cheaper?

LUPKIN: So I do not know for positive, however capsules sometimes are cheaper to make than medication given by injection. The injector pens may also add to the associated fee. As for Novo Nordisk, it hasn’t introduced its sticker worth but. Nevertheless, as a part of a cope with the Trump administration, it mentioned that for sufferers not utilizing their insurance coverage, they’d supply it for $149 a month. That is a less expensive direct-to-consumer worth than for injectables, so it might be an encouraging signal. The corporate says entry is a matter that it is engaged on with different elements of the drug provide chain.

RASCOE: That was NPR prescribed drugs correspondent Sydney Lupkin. Thanks a lot, Sydney.

LUPKIN: You wager.

Copyright © 2025 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.

Accuracy and availability of NPR transcripts could fluctuate. Transcript textual content could also be revised to right errors or match updates to audio. Audio on npr.org could also be edited after its unique broadcast or publication. The authoritative report of NPR’s programming is the audio report.